Sartorius Stedim Biotech Reports Solid Half-Year 2025 Results

Sartorius Stedim Biotech has announced its half-year results for 2025, showing strong growth in sales revenue and profitability. The company's sales revenue increased by 9.4% in constant currencies, reaching 1,490 million euros. Underlying EBITDA saw an even larger increase of 19.3% to 462 million euros, improving the margin to 31.0%.

The positive results were driven by consistent demand for high-margin consumables and single-use solutions, with all regions posting sales growth. The Americas led with an 11% rise, while EMEA and Asia/Pacific followed with 8.7% and 8.1% increases, respectively.

Investments in research and production infrastructure were slightly lower than the previous year, while assets and equity remained stable. Management maintains a positive outlook for 2025, confirming guidance for continued growth, despite industry volatility and geopolitical uncertainties.